• Publications
  • Influence
Class of antiretroviral drugs and the risk of myocardial infarction.
BACKGROUND We have previously demonstrated an association between combination antiretroviral therapy and the risk of myocardial infarction. It is not clear whether this association differs accordingExpand
  • 1,004
  • 37
  • Open Access
Combination antiretroviral therapy and the risk of myocardial infarction.
BACKGROUND It remains controversial whether exposure to combination antiretroviral treatment increases the risk of myocardial infarction. METHODS In this prospective observational study, weExpand
  • 1,241
  • 31
  • Open Access
Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study
Objective: To determine the prevalence of risk factors for cardiovascular disease (CVD) among HIV-infected persons, and to investigate any association between such risk factors, stage of HIV disease,Expand
  • 983
  • 26
Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients.
Despite recent advances in the management of hepatitis and HIV co-infection, there is no clear consensus among hepatology, infectious diseases and virology experts on treatment of co-infections andExpand
  • 391
  • 23
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis.
CONTEXT Presence of low-frequency, or minority, human immunodeficiency virus type 1 (HIV-1) drug resistance mutations may adversely affect response to antiretroviral treatment (ART), but evidenceExpand
  • 312
  • 15
  • Open Access
Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis.
BACKGROUND Single-dose nevirapine (NVP) is the main option for the prevention of mother-to-child transmission (PMTCT) of HIV-1 in countries with limited resources. However, the use of single-dose NVPExpand
  • 252
  • 14
  • Open Access
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies
Objective:To estimate the prognosis over 5 years of HIV-1-infected, treatment-naive patients starting HAART, taking into account the immunological and virological response to therapy. Design:AExpand
  • 295
  • 12
Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment.
HIV infection results in CD4+ T cell deficiency, but efficient combination antiretroviral therapy (c-ART) restores T cells and decreases morbidity and mortality. However, immune restoration by c-ARTExpand
  • 313
  • 11
  • Open Access
Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study
Aims HIV-infected patients receiving combination antiretroviral therapy may experience metabolic complications, potentially increasing their risk of cardiovascular diseases (CVDs). Furthermore,Expand
  • 283
  • 11
  • Open Access
Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study
Objective:To investigate any emerging trends in causes of death amongst HIV-positive individuals in the current cART era, and to investigate the factors associated with each specific cause of death.Expand
  • 373
  • 10
  • Open Access